biote director receives option and RSU awards

biote Corp. director Stephen Mark Cone received new equity awards in the form of options and deferred settlement RSUs.

Rhea-AI Filing Summary

biote Corp. director Stephen Mark Cone received new equity awards in the form of options and deferred settlement RSUs. He was granted stock options for 130,000 shares of Class A Common Stock at an exercise price of $2.20 per share, vesting in full on the earlier of May 12, 2027 or the day prior to the 2027 annual meeting, subject to continued service.

He also received 31,481 Deferred Settlement RSUs, each economically equivalent to one share of Class A Common Stock. These RSUs are fully vested upon grant, but settlement is deferred until his separation from service. Following these awards, he holds 130,000 options and 69,822 Deferred Settlement RSUs directly.

Insider Trade Summary

Grant/Award: 161,481 shares

Grant/Award 2 txns

Insider Cone Stephen Mark

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Settlement RSU	31,481	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	130,000	$0.00	$0.00

Holdings After Transaction: Deferred Settlement RSU — 69,822 contracts (Direct); Stock Option (Right to Buy) — 130,000 contracts (Direct)

Footnotes (3)

1. F1. Each Deferred Settlement RSU is the economic equivalent of one share of Issuer Class A Common Stock.
2. F2. The Deferred Settlement RSUs are fully vested upon grant, but settlement will be deferred until the date of the Reporting Person's separation from service.
3. F3. All shares subject to the option award shall vest on the earlier of May 12, 2027 or the day prior to the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Stock options granted: 130,000 options Deferred Settlement RSUs granted: 31,481 RSUs Options held after grant: 130,000 options +2 more

5 metrics

Stock options granted 130,000 options Exercise price <money>$2.20</money> per share; vesting by May 2027

Deferred Settlement RSUs granted 31,481 RSUs Fully vested upon grant; settlement at separation from service

Options held after grant 130,000 options Total options following the reported award

Deferred Settlement RSUs held after grant 69,822 RSUs Total RSUs following the reported award

Option expiration date <date>May 11, 2036</date> Expiration of newly granted stock options

Key Terms

Deferred Settlement RSU, economic equivalent, separation from service, vest

4 terms

Deferred Settlement RSU financial

"Each Deferred Settlement RSU is the economic equivalent of one share of Issuer Class A Common Stock."

economic equivalent financial

"Each Deferred Settlement RSU is the economic equivalent of one share of Issuer Class A Common Stock."

separation from service financial

"settlement will be deferred until the date of the Reporting Person's separation from service."

vest financial

"All shares subject to the option award shall vest on the earlier of May 12, 2027 or the day prior to the date of the Issuer's 2027 Annual Meeting of Stockholders"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity awards did biote (BTMD) disclose for Stephen Mark Cone?

biote disclosed that director Stephen Mark Cone received 130,000 stock options and 31,481 Deferred Settlement RSUs. Both awards relate to Class A Common Stock and were reported as compensation grants rather than open-market purchases or sales.

What is the exercise price and vesting schedule of Cone's new biote (BTMD) stock options?

Cone’s new options cover 130,000 shares at an exercise price of $2.20 per share. All option shares vest on the earlier of May 12, 2027 or the day before the 2027 annual stockholders meeting, assuming his continuous service.

How do the Deferred Settlement RSUs granted to Cone at biote (BTMD) work?

Each Deferred Settlement RSU equals one share of Class A Common Stock. These RSUs are fully vested when granted, but the actual share settlement is deferred until Stephen Mark Cone’s separation from service with the company.

How many Deferred Settlement RSUs does Stephen Mark Cone hold after this biote (BTMD) Form 4?

After this filing, Cone holds 69,822 Deferred Settlement RSUs directly. The latest grant added 31,481 RSUs, and each unit is economically equivalent to one share of the company’s Class A Common Stock.

Are Stephen Mark Cone’s biote (BTMD) Form 4 transactions open-market buys or sells?

The reported transactions are equity compensation grants, not open-market trades. Both the stock options and Deferred Settlement RSUs were recorded with code A as grant, award, or other acquisition rather than purchases or sales in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/13/2026 - 06:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cone Stephen Mark

(Last) (First) (Middle)

C/O BIOTE CORP.

1875 W. WALNUT HILL LN #100

(Street)

IRVING TEXAS 75038

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
biote Corp. [ BTMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Settlement RSU	(1)	05/12/2026		A		31,481		(2)	(2)	Class A Common Stock	31,481	$0.00	69,822	D
Stock Option (Right to Buy)	$2.2	05/12/2026		A		130,000		(3)	05/11/2036	Class A Common Stock	130,000	$0.00	130,000	D

Explanation of Responses:

1. Each Deferred Settlement RSU is the economic equivalent of one share of Issuer Class A Common Stock.

2. The Deferred Settlement RSUs are fully vested upon grant, but settlement will be deferred until the date of the Reporting Person's separation from service.

3. All shares subject to the option award shall vest on the earlier of May 12, 2027 or the day prior to the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Kendal McNeely, as Attorney-in-Fact for Mark Cone	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)